ReviewHistochemistry and cell biology2026
Cellular accumulation of lipofuscin in the heart: implications in health and disease.
Review in Histochemistry and cell biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lipofuscin is a subcellular pigmented granule that has long been considered a sign of wear-and-tear and aging. This granule cannot be degraded but may be diluted by cell division. In the heart, lipofuscin can be easily identified in cardiomyocytes where proliferative capacity is limited, and to a lesser extent in other cardiac cell types, by their characteristic morphological features. They appear as yellow-brown granules in histopathology sections reflecting their lipid origins, and as heterogenous membrane-bound bodies containing a mix of lipid and electron-lucent content in transmission electron microscopy. Lipofuscin was originally considered a mere byproduct of age-related cell senescence but studies over the past three decades have indicated that its role and mechanism of formation may be far more complex. In this review, we examine how lipofuscin is formed and its implications in aging and diseases of the heart. While the focus of this review is on lipofuscin in the two most predominate cell types of the heart, cardiomyocytes and fibroblasts, we also touch on the presence of lipofuscin in the vasculature in certain disease phenotypes that are directly relevant to cardiovascular health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.